Two Sigma Advisers
TSHA icon

Two Sigma Advisers’s Taysha Gene Therapies TSHA Stock Holding History

Two Sigma Advisers’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-139,581
Closed -$768K – 1994
2025
Q4 		$768K Buy
+139,581
New +$678K ﹤0.01% 1614
2022
Q4 		– Sell
-87,700
Closed -$169K – 2704
2022
Q3 		$169K Sell
87,700
-18,100
-17% -$65.7K ﹤0.01% 2235
2022
Q2 		$394K Sell
105,800
-30,500
-22% -$121K ﹤0.01% 2026
2022
Q1 		$889K Buy
136,300
+102,200
+300% +$764K ﹤0.01% 1692
2021
Q4 		$397K Buy
+34,100
New +$514K ﹤0.01% 2026

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Advisers's TSHA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 139,581 shares — an estimated $768K sold.

Two Sigma Advisers first reported a position in TSHA in Q4 2021 and held it in 5 quarters. The position peaked at $889K in Q1 2022. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Two Sigma Advisers reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 139,581 Taysha Gene Therapies shares in Q1 2026, an estimated $768K.
  • Two Sigma Advisers first reported a position in Taysha Gene Therapies in Q4 2021 and held it in 5 quarters.
  • Two Sigma Advisers's Taysha Gene Therapies position peaked at $889K in Q1 2022.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.